Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Feb 16, 2023 10:00am
148 Views
Post# 35289636

Why Now?

Why Now?I do not want to criticize management's effort to communicate, so I appreciate the PR even though there wasn't much meat on the bone.However, I am curious as to why now? Why issue the earning PR today, then less than 24 hours later issue this "Update" PR? 

If there was more material information in today's update I would have expected it was so Christian could speak more freely at the conference next week, but I don't know if name dropping the SAC is all that material? 

So then it begs the question as to what the business update will be along with the earnings on the 28th? Is it going to be a scripted rehash of the PR with little new information or will they surprise with some NASH news? I would not hold my breath, but who knows with this bunch. 

The actions the company is taking to restart are rational, albeit slower than some investors would have hoped. However I don't get a sense of urgency from management with regards to where the current Spare Price is sitting. Yes, as investors we would like them to pump it all the time, but my comment comes from the internal perspective. They are sub $1 on the NASDAQ and without any action will receive written warning and flirt with delisting. The company has been down that path before and it is not a pleasant one. So what are they going to do to ensure they don't lose the listing and potentially their access to US broker funding along with it? 

All these questions are on my mind and then I see the CEO, Board Chair, and a Board Member carousing at a gala!?! Again, nothing is stopping them, but to actively post about it is like posing for a photo as the house burns down.  
<< Previous
Bullboard Posts
Next >>